# Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Source: https://onco.cc/trials/nct01767714/  
OnCo record `nct01767714` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Filgrastim and Plerixafor in Non-Hodgkin lymphoma, run by Sanofi, completed.

## Summary

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation is a phase 3 interventional study registered as NCT01767714 by Sanofi, with 100 participants recorded, started 2013-04 and reaching its primary completion in 2014-11. Interventions recorded: Granulocyte-colony stimulating factor (G-CSF), Plerixafor, Placebo. Conditions recorded: Non-Hodgkin's Lymphoma.

Linked to the drug Plerixafor because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01767714
- Phase: 3
- Setting: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
- Sponsor: Sanofi
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT01767714: https://clinicaltrials.gov/study/NCT01767714

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Plerixafor](https://onco.cc/drugs/plerixafor/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct01767714.json